20th Annual NATA Symposium
The 20th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis took place on April 4-5, 2019 in Berlin, Germany.
This year, 580 delegates from 38 countries participated in the symposium and there was a record local attendance of 167 attendees from Portugal.
Download the NATA Conference App, “NATA Forum”, on the App Store or the Play Store to access presentation webcasts.
The Abstract Book can be downloaded here.
Please click on the link below for more information
20th Annual Symposium General Information
Focused Update: Perioperative Management of Jehovah’s Witness Patients in Relation to Their Refusal of Allogeneic Blood Transfusion
Jehovah's Witness (JW) patients strictly refuse allogeneic blood transfusion (red blood cells, plasma and platelets), even in the presence of life-threatening anemia and/or coagulopathy. However, today JW patients can undergo major surgical procedures without facing an excessive risk of death—provided that a prospectively conceived and structured perioperative management is applied.
In a Nataonline Focused Update, Prof. Oliver Habler, Department of Anesthesiology, Surgical Intensive Care Medicine and Pain Therapy, Krankenhaus Nordwest GmbH, Frankfurt, Germany, reviews the perioperative management of JW patients with emphasis on the following cornerstones: (1) the preoperative optimization of cardiopulmonary status and the correction of preoperative anemia and coagulopathy, (2) the perioperative collection of autologous blood, (3) the minimization of perioperative blood loss and (4) the utilization of the organism’s natural tolerance to anemia and its acute accentuation in the case of life-threatening anemia.
Focused update: The management of massive hemorrhage/transfusion in civilian trauma
The management of massive hemorrhage/transfusion in trauma has evolved considerably in the past few years. Based on a consensus established in 2005, several civilian trauma centers have adopted a restrictive approach to the administration of crystalloids in view of minimizing hemodilution, along with the transfusion of red blood cells (RBC), fresh frozen plasma (FFP) and platelet concentrates (PC) in a 1:1:1 ratio. In a Nataonline Focused Update, Professor Jean-François discusses the evidence supporting this strategy.